Figure 6.
Schematic for intestinal drug transport using WGA-conjugated lipid NPs targeted to intestinal mucosal cells: (a,c) fluid phase endocytosis, (b) binding of WGA to glycoproteins followed by receptor-mediated endocytosis, (d) transcellular transport, (e) endocytosis might be blocked by absence of receptors or unsuitable conditions